IN2014MN01724A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01724A
IN2014MN01724A IN1724MUN2014A IN2014MN01724A IN 2014MN01724 A IN2014MN01724 A IN 2014MN01724A IN 1724MUN2014 A IN1724MUN2014 A IN 1724MUN2014A IN 2014MN01724 A IN2014MN01724 A IN 2014MN01724A
Authority
IN
India
Prior art keywords
immune cell
moiety
further moiety
molecule
unwanted cells
Prior art date
Application number
Other languages
English (en)
Inventor
Mark Cobbold
David Millar
Original Assignee
Univ Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45991852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN01724(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Birmingham filed Critical Univ Birmingham
Publication of IN2014MN01724A publication Critical patent/IN2014MN01724A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN1724MUN2014 2012-02-28 2013-02-28 IN2014MN01724A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1203442.7A GB201203442D0 (en) 2012-02-28 2012-02-28 Immunotherapeutic molecules and uses
PCT/GB2013/050499 WO2013128194A1 (en) 2012-02-28 2013-02-28 Immunotherapeutic molecules and uses

Publications (1)

Publication Number Publication Date
IN2014MN01724A true IN2014MN01724A (de) 2015-05-29

Family

ID=45991852

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1724MUN2014 IN2014MN01724A (de) 2012-02-28 2013-02-28

Country Status (9)

Country Link
US (3) US9822180B2 (de)
EP (1) EP2819701B2 (de)
JP (1) JP6273215B2 (de)
CN (1) CN104321081A (de)
AU (1) AU2013227477B2 (de)
CA (1) CA2865482A1 (de)
GB (1) GB201203442D0 (de)
IN (1) IN2014MN01724A (de)
WO (1) WO2013128194A1 (de)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6130307B2 (ja) * 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
US20140161800A1 (en) 2011-04-22 2014-06-12 John W. Blankenship Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9540439B2 (en) 2012-10-08 2017-01-10 St. Jude Children's Research Hospital Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis
PT2992017T (pt) 2013-05-02 2021-01-29 Anaptysbio Inc Anticorpos dirigidos contra a morte programada 1 (pd-1)
US10633453B2 (en) 2013-05-28 2020-04-28 Kaohsiung Medical University Antibody locker for the inactivation of protein drug
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
HRP20220553T1 (hr) * 2013-07-25 2022-06-10 Cytomx Therapeutics Inc. Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela
CN112390883A (zh) 2013-12-17 2021-02-23 基因泰克公司 抗cd3抗体及使用方法
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CN114081946A (zh) 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
WO2016014974A2 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
JP2017529853A (ja) * 2014-09-25 2017-10-12 アムジエン・インコーポレーテツド プロテアーゼにより活性化可能な二重特異性タンパク質
EP3253419A1 (de) 2015-02-02 2017-12-13 The University of Birmingham Zieleinheit-peptidepitopkomplexe mit einer vielzahl von t-zell-epitopen
WO2016149201A2 (en) * 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3778640A1 (de) * 2015-05-01 2021-02-17 Genentech, Inc. Maskierte anti-cd3-antikörper und verfahren zur verwendung
US11400157B2 (en) 2015-05-13 2022-08-02 Chugai Seiyaku Kabushiki Kaisha Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
KR20190080992A (ko) 2015-05-21 2019-07-08 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
CN108472365A (zh) 2015-10-30 2018-08-31 艾丽塔生物治疗剂公司 用于肿瘤转导的组合物和方法
CN108602872A (zh) 2015-10-30 2018-09-28 艾丽塔生物治疗剂公司 用于治疗癌症的组合物和方法
ES2873846T5 (en) * 2015-11-19 2025-06-23 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
AU2017219859A1 (en) * 2016-02-16 2018-08-09 Dana-Farber Cancer Institute, Inc. Immunotherapy compositions and methods
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
KR20230041739A (ko) * 2016-03-08 2023-03-24 매버릭 테라퓨틱스, 인크. 유도성 결합 단백질 및 사용 방법
BR112018016281A2 (pt) * 2016-03-22 2019-01-02 F. Hoffmann-La Roche Ag molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo
CN109195620B (zh) 2016-04-07 2022-06-28 约翰霍普金斯大学 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
EP3493844A4 (de) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. Einzeldomänen-serumalbuminbindendes protein
PL3461261T3 (pl) 2016-05-20 2025-11-12 Harpoon Therapeutics, Inc. Białka wiążące jednołańcuchowy fragment zmienny CD3
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7461741B2 (ja) * 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US11155624B2 (en) 2016-11-01 2021-10-26 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
KR20210087108A (ko) 2016-11-23 2021-07-09 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
MX2019006045A (es) 2016-11-23 2019-11-11 Harpoon Therapeutics Inc Proteinas triespecificas dirigidas a psma y metodos de uso.
KR102533814B1 (ko) 2016-11-28 2023-05-19 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
KR20240018673A (ko) * 2016-11-28 2024-02-13 추가이 세이야쿠 가부시키가이샤 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
EA201991353A1 (ru) * 2016-12-09 2019-11-29 Двухвалентные антитела, маскированные спирализованными спиралями
CN110382545A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法
IL268554B2 (en) 2017-02-08 2025-03-01 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3235295C (en) 2017-02-20 2024-11-19 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
US20210130494A1 (en) * 2017-02-22 2021-05-06 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
TW202515920A (zh) 2017-04-11 2025-04-16 美商因荷布瑞克斯生物科學公司 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
US20200115461A1 (en) * 2017-05-03 2020-04-16 Harpoon Therapeutics, Inc. Compositions and methods for adoptive cell therapies
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
KR20240170847A (ko) 2017-09-08 2024-12-04 다케다 야쿠힌 고교 가부시키가이샤 제약된 조건적으로 활성화된 결합 단백질
PL3694529T3 (pl) 2017-10-13 2024-12-16 Harpoon Therapeutics, Inc. Trójswoiste białka i sposoby zastosowania
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
IL321773A (en) 2017-10-14 2025-08-01 Cytomx Therapeutics Inc Activatable antibodies and methods for preparing them
JP7482630B2 (ja) 2017-11-28 2024-05-14 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
TWI818934B (zh) 2017-11-28 2023-10-21 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
US20200385440A1 (en) * 2017-12-07 2020-12-10 Janux Therapeutics, Inc. Modified bispecific t cell receptors
WO2019118918A1 (en) 2017-12-15 2019-06-20 Aleta Biotherapeutics Inc. Cd19 variants
WO2019148445A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
CA3089287A1 (en) 2018-02-08 2019-08-15 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
US12215157B2 (en) 2018-02-20 2025-02-04 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
CA3115461A1 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
KR20210006913A (ko) 2018-04-11 2021-01-19 인히브릭스, 인크. 제한된 ｃｄ3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
CN112437672A (zh) * 2018-05-07 2021-03-02 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
MX2020012217A (es) 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
US20210253672A1 (en) * 2018-05-30 2021-08-19 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule containing single domain antibody
JP7414736B2 (ja) 2018-05-30 2024-01-16 中外製薬株式会社 アグリカン結合ドメインおよび運搬部分を含むポリペプチド
EP3802831A4 (de) * 2018-05-30 2022-07-27 Chugai Seiyaku Kabushiki Kaisha Polypeptid mit il-1r1-bindungsdomäne und trägereinheit
JP7418364B2 (ja) * 2018-07-02 2024-01-19 ザ ジェネラル ホスピタル コーポレイション 抗体腫瘍ターゲティングアセンブリ複合体
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
JP2021530243A (ja) 2018-07-25 2021-11-11 アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. 新規ｉｌ−２１プロドラッグおよびそれを使用する方法
MA53284A (fr) * 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
EP3833392A4 (de) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. Multispezifische bindende proteine zur bindung von cd33, nkg2d und cd16 sowie verfahren zur verwendung
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
CA3121813A1 (en) * 2018-12-14 2020-06-18 Proviva Therapeutics (Hong Kong) Limited Il-15 compositions and methods of use thereof
CN119896730A (zh) * 2018-12-17 2025-04-29 雷维托普有限公司 双免疫细胞衔接物
CN120484127A (zh) 2019-03-05 2025-08-15 武田药品工业有限公司 受约束的条件性活化的结合蛋白
KR20210153092A (ko) 2019-04-15 2021-12-16 퀴셀 세라퓨틱스 엘엘씨 암 치료에 사용하기 위한, 마스킹된 유형 i 인터페론(ifna 및 ifnb) 및 종양 항원에 대한 항체를 포함하는 융합 단백질 조성물
EP3725370A1 (de) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modifizierte anti-pd-l1-antikörper und verfahren und verwendungen zur behandlung einer neurodegenerativen erkrankung
WO2020223108A1 (en) * 2019-05-02 2020-11-05 The General Hospital Corporation Teac and attac immunooncology compositions and methods
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN113905757A (zh) 2019-06-05 2022-01-07 中外制药株式会社 抗体切割位点结合分子
AR120741A1 (es) 2019-12-13 2022-03-16 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso
AU2021208642B2 (en) * 2020-01-17 2025-06-05 Immunelogic Therapeutics, Inc. Pro-antibody that reduces off-target toxicity
EP4090686A4 (de) * 2020-01-17 2024-03-27 Immune Targeting Inc. Pro-antikörper, der die off-target-toxizität reduziert
KR20220144841A (ko) 2020-02-21 2022-10-27 하푼 테라퓨틱스, 인크. Flt3 결합 단백질 및 사용 방법
KR20220166814A (ko) 2020-04-09 2022-12-19 싸이톰스 테라퓨틱스, 인크. 활성화 가능한 항체를 함유하는 조성물
IL297412A (en) 2020-05-04 2022-12-01 Immunorizon Ltd Precursor tri-specific antibody constructs and methods of use thereof
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
CA3177239A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific antibodies
WO2021260064A1 (en) 2020-06-25 2021-12-30 F. Hoffmann-La Roche Ag Anti-cd3/anti-cd28 bispecific antigen binding molecules
EP4196231A1 (de) 2020-08-14 2023-06-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Chimäre antigenrezeptor-t-zellen zur behandlung von autoimmunität
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
IL302396A (en) 2020-11-04 2023-06-01 Genentech Inc Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
CA3196844A1 (en) 2020-11-25 2022-06-02 Raphael Rozenfeld Tumor-specific cleavable linkers
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CA3201621A1 (en) 2020-12-03 2022-06-09 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
MX2023006817A (es) 2020-12-09 2023-08-14 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
EP4301774A4 (de) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc Verfahren zur behandlung von krebs mit multispezifischen bindungsproteinen zur bindung von nkg2d, cd16 und einem tumorassoziierten antigen
TW202243689A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥
AU2022273541A1 (en) 2021-05-14 2023-11-30 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
US20240309089A1 (en) * 2021-07-13 2024-09-19 Sinomab Bioscience Limited Methods of treating neurological diseases
AR128876A1 (es) 2022-03-28 2024-06-19 Hoffmann La Roche Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
AU2023250649A1 (en) 2022-04-04 2024-11-14 The Regents Of The University Of California Genetic complementation compositions and methods
AR129061A1 (es) 2022-04-13 2024-07-10 Genentech Inc Composiciones farmacéuticas de mosunetuzumab y métodos de uso
EP4594353A1 (de) 2022-09-28 2025-08-06 F. Hoffmann-La Roche AG Verbesserte protease-aktivierbare bispezifische t-zell-antikörper
CN121127500A (zh) 2023-04-07 2025-12-12 达科纳治疗有限公司 针对激活素a受体样1型(alk1)的双特异性激动性抗体

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3578568A (en) 1968-11-29 1971-05-11 Atlantic Richfield Co Purification of low molecular weight epoxides by extractive distillation with a glycol or glycol ether
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0659438A1 (de) 1993-12-23 1995-06-28 Boehringer Mannheim Gmbh Konjugate, bestehend aus peptidischen T-Zell Antigenen und eine Zell-bindende Gruppe, und deren Verwendung in der Therapie
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US20040197336A1 (en) 1995-05-03 2004-10-07 Self Colin Henry Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety
AU5509296A (en) * 1995-05-03 1996-11-21 Colin Henry Self Bispecific antibodies in which the binding capability is rev ersibly inhibited by a photocleavable moiety
WO1997023237A1 (en) 1995-12-22 1997-07-03 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
WO1998010651A1 (en) 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
GB9624993D0 (en) 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy
WO1998041641A1 (en) 1997-03-20 1998-09-24 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
JP2002510325A (ja) 1997-07-10 2002-04-02 メルク エンド カンパニー インコーポレーテッド 前立腺癌の治療に有用なコンジュゲート
JP4169478B2 (ja) 1998-04-21 2008-10-22 マイクロメット アーゲー Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
DK1100830T3 (da) 1998-07-28 2004-01-19 Micromet Ag Heterominiantistoffer
WO2000058362A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
WO2002044197A2 (en) 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
EP1448584B1 (de) 2001-09-26 2010-05-19 The Government of the United States of America as represented by The Secretary of Health and Human Services Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen
EP1451226A1 (de) 2001-11-30 2004-09-01 Crucell Holland B.V. Konjugat zum targeting von antigen präsentierenden zellen, eine antigen präsentierende zelle mit einem solchen konjugat, ihre verwendung als impfstoff oder medikament und verfahren zu ihrer herstellung
EP2295468B1 (de) 2002-02-14 2015-07-08 Immunomedics, Inc. Anti-CD20 Antikörper und Fusionsproteine davon und Anwendungsverfahren
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
SI2357006T1 (sl) 2002-07-31 2016-01-29 Seattle Genetics, Inc. Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
EP1590372A2 (de) 2003-02-06 2005-11-02 Micromet AG Trimäre polypeptidkonstruktion zur erregung eines dauerhaften t zellresponses
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
KR20120125634A (ko) * 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
EP2186527A1 (de) 2003-11-28 2010-05-19 Micromet AG Polypeptide enthaltende Zusammensetzungen
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
GB0404187D0 (en) 2004-02-25 2004-03-31 Biotransformations Ltd Binding agents
US20060045881A1 (en) 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
GT200500255A (es) 2004-09-10 2006-04-10 Anticuerpos anti-5ta humanizados y conjugados anticuerpo anti-5ta/calicheamicina
ATE530198T1 (de) 2005-02-16 2011-11-15 Univ Zuerich Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt ist
EP1948802A4 (de) 2005-10-13 2009-01-14 Virexx Medical Corp Chimäres antigen mit hepatitis-c-virus-polypeptid und fc-fragment zum hervorrufen einer immunantwort
ATE458000T1 (de) 2005-11-18 2010-03-15 Dabur Pharma Ltd Zielgerichtete fusionsproteine für die krebstherapie
GB0605702D0 (en) 2006-03-21 2006-05-03 Biotransformations Ltd Materials and methods for immune cell stimulation
US20080171059A1 (en) 2006-08-07 2008-07-17 Shanshan Wu Howland Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens
CA2668017A1 (en) 2006-10-30 2008-05-08 Viventia Biotech Inc. Improved conjugates
WO2008063113A1 (en) 2006-11-20 2008-05-29 Cepep Iii Ab Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf
ATE525392T1 (de) 2007-01-30 2011-10-15 Epivax Inc Regulatorische t-zellen-epitopen sowie zusammensetzungen damit und anwendungen davon
MX2009008140A (es) 2007-02-02 2009-10-26 Baylor Res Inst Vacunas a base de antigeno dirigido a dcir expresado en celulas que presentan antigeno.
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
GB0716160D0 (en) * 2007-08-17 2007-09-26 Biotransformations Ltd Materials and methods for treating cancers which express folate receptors
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
ES2582603T5 (es) 2008-10-01 2022-12-02 Amgen Res Munich Gmbh Anticuerpos biespecíficos de cadena sencilla con especificidad por antígenos diana de alto peso molecular
US20110178279A1 (en) * 2009-08-03 2011-07-21 Williams John C Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies
US20100189727A1 (en) 2008-12-08 2010-07-29 Tegopharm Corporation Masking Ligands For Reversible Inhibition Of Multivalent Compounds
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
CN105837691B (zh) 2009-03-10 2021-06-29 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
WO2011056721A2 (en) 2009-11-05 2011-05-12 Center For Molecular Medicine And Immunology Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
US9193791B2 (en) 2010-08-03 2015-11-24 City Of Hope Development of masked therapeutic antibodies to limit off-target effects
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
RU2013110876A (ru) 2010-08-24 2014-09-27 Рош Гликарт Аг Активируемые биспецифические антитела
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013139789A1 (en) 2012-03-19 2013-09-26 Deutsches Krebsforschungszentrum B-cell receptor complex binding proteins containing t-cell epitopes
CA2871458C (en) 2012-04-27 2020-06-23 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
EP2863948B1 (de) 2012-06-22 2018-10-24 Cytomx Therapeutics Inc. Anti-jagged-1/jagged-2-kreuzreaktive antikörper, aktivierbare anti-jagged-antikörper und anwendungsverfahren dafür
US9856314B2 (en) 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
WO2014052462A2 (en) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
AU2014204015A1 (en) 2013-01-04 2015-07-09 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems
UY35459A (es) 2013-03-15 2014-10-31 Bayer Healthcare Llc Anticuerpos profármaco contra el inhibidor de la vía del factor tisular
US9517276B2 (en) 2013-06-04 2016-12-13 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
HRP20220553T1 (hr) 2013-07-25 2022-06-10 Cytomx Therapeutics Inc. Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela
US20150087810A1 (en) 2013-09-25 2015-03-26 Cytomx Therapeutics, Inc. Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
BR112016017649B1 (pt) 2014-01-31 2024-01-30 Cytomx Therapeutics, Inc Polipeptídeo isolado compreendendo substratos de matriptase e de ativador do plasminogênio u e outras porções cliváveis, composição farmacêutica compreendendo o dito polipeptídeo, bem como métodos para produzir e fabricar um polipeptídeo isolado compreendendo uma porção clivável e uso da composição farmacêutica e quantidade terapeuticamente eficaz da dita composição no tratamento de um distúrbio ou doença
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same

Also Published As

Publication number Publication date
CA2865482A1 (en) 2013-09-06
JP6273215B2 (ja) 2018-01-31
EP2819701A1 (de) 2015-01-07
EP2819701B1 (de) 2018-07-25
AU2013227477A1 (en) 2014-09-18
US9650445B2 (en) 2017-05-16
GB201203442D0 (en) 2012-04-11
EP2819701B2 (de) 2021-06-02
US20150183875A1 (en) 2015-07-02
CN104321081A (zh) 2015-01-28
AU2013227477B2 (en) 2017-03-23
WO2013128194A1 (en) 2013-09-06
US20180105599A1 (en) 2018-04-19
US10106621B2 (en) 2018-10-23
US20160039942A1 (en) 2016-02-11
JP2015509952A (ja) 2015-04-02
US9822180B2 (en) 2017-11-21

Similar Documents

Publication Publication Date Title
IN2014MN01724A (de)
IN2014DN06104A (de)
MY185016A (en) Progenitor cells of mesodermal lineage
IN2015DN00143A (de)
EP4582090A3 (de) Zusammensetzung mit pegylierter arginin-deiminase
AU2012335543A8 (en) HER3 antibodies and uses thereof
AU334338S (en) Electronic housing portion
AU334280S (en) Electronic housing portion
AU348733S (en) Carburetor main body
AU334339S (en) Electronic housing portion
AU339157S (en) Carburettor
AU341122S (en) Intake manifold
IN2015DN03795A (de)
IN2015DN00636A (de)
AU341133S (en) Carburetor main body
IN2014DN08721A (de)
EP4458361A3 (de) Modulation der ube3a-ats-expression
PH12015501083A1 (en) Novel pyridine derivatives
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MY168166A (en) Polymer and Composition Including Same, and Adhesive Composition
AU342351S (en) Automobile
NZ627480A (en) Inhibitors of iap
IN2014KN02745A (de)
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
IN2015DN00962A (de)